CA-C3.AI
15.9.2020 15:02:13 CEST | Business Wire | Press release
C3.ai , a leading enterprise artificial intelligence (AI) software provider for accelerating digital transformation, today welcomes data scientists, developers, researchers, and creative thinkers from around the world to participate in the C3.ai™ COVID-19 Grand Challenge . The competition invites participants to leverage data science techniques in new and innovative ways to generate insights that previously were neither apparent nor achievable.
“The C3.ai COVID-19 Grand Challenge represents an opportunity to inform decision makers at the local, state, and federal levels and transform the way the world confronts this pandemic,” said Thomas M. Siebel, CEO of C3.ai. “As with the C3.ai COVID-19 Data Lake and the C3.ai Digital Transformation Institute , this initiative will tap our community’s collective IQ to make important strides toward necessary, innovative solutions that will help solve a global crisis.”
What Makes a Great Solution
In response to the acute challenges the world faces, the judging panel will prioritize data science projects that help us understand and mitigate the spread of the virus; improve the response capabilities of the medical community; minimize the impact of this disease on society; and help policymakers navigate responses to COVID-19.
Projects may address, but are not limited to:
- Applying machine learning and other AI methods to mitigate the spread of the COVID-19 pandemic
- Genome-specific COVID-19 medical protocols, including precision medicine of host responses
- Biomedical informatics methods for drug design and repurposing
- Design and sharing of clinical trials for collecting data on medications, therapies, and interventions
- Modeling, simulation, and prediction for understanding COVID-19 propagation and efficacy of interventions
- Logistics and optimization analysis for design of public health strategies and interventions
- Rigorous approaches to designing sampling and testing strategies
- Data analytics for COVID-19 research harnessing private and sensitive data
- Improving societal resilience in response to the spread of the COVID-19 pandemic
- Broader efforts in biomedicine, infectious disease modeling, response logistics and optimization, public health efforts, tools, and methodologies around the containment of rising infectious diseases and response to pandemics.
Award Criteria
A panel of judges will evaluate submissions on the extent to which they derive insights, leveraging data science techniques (e.g., statistical analyses, AI/ML algorithms, optimization approaches, etc.) that were not obvious before.
- Pat House, Vice Chairman, C3.ai
- Mike Callagy, County Manager, County of San Mateo
- Richard Levin, Board of Directors, C3.ai and Former President Emeritus, Yale University
- S. Shankar Sastry, Co-Director, C3.ai Digital Transformation Institute and Professor of Electrical Engineering & Computer Sciences, UC Berkeley
- Zico Kolter, Associate Professor of Computer Science, Carnegie Mellon University
The competition is now open with a registration deadline of Oct. 25 and a submission deadline of Nov. 18, 2020. To learn more about how to submit proposals, please visit https://c3.ai/grand-challenge/ .
By Dec. 9, 2020, C3.ai will announce seven competition winners and award $200,000 in cash prizes to the honorees.
- Prizes – There will be one Grand Prize of $100,000, two second-place awards of $25,000 each, and four third-place awards of $12,500 each.
- Publication – The winners will have their work published by C3.ai.
C3.ai COVID-19 Data Lake Expands
The C3.ai™ COVID-19 Data Lake , launched in April 2020, continues to expand and now consists of 40 unique datasets, making it the largest unified, federated image of COVID-19 data in the world. Researchers and developers worldwide can access this free, open-source resource to build models, run analytics, develop tools, and more, without the time and effort of data wrangling.
As part of the C3.ai COVID-19 Grand Challenge, applicants will be required to use the C3.ai COVID-19 Data Lake as a resource to generate new and innovative solutions.
The latest datasets to be integrated into the Data Lake include:
- CDC: Weekly Updates by Select Demographic Characteristics
- COVID Racial Data Tracker from the COVID Tracking Project at The Atlantic
- US Census Bureau: County Population by Age, Sex, Race and Hispanic Origin
- US Bureau of Labor Statistics: County Unemployment Statistics
- Realtor.com: Housing Indicators
- Bureau of Economic Analysis: GDP and Economic Profile by County
- Opportunity Insights: Economic Tracker
- Swayable and TapResearch: COVID-19 Tracker Poll
For additional information about the C3.ai COVID-19 Data Lake, please visit: https://c3.ai/covid
To learn more about the C3.ai COVID-19 Grand Challenge, please visit https://c3.ai/grand-challenge/ .
About C3.ai
C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI® Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turnkey AI applications. The core of the C3.ai offering is a revolutionary, model-driven AI architecture that dramatically enhances data science and application development.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005410/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
